In Billing
Mar 2nd, 2012
If you commonly report CPT® 11980 Subcutaneous hormonal pellet implantation beneath the skin along with either HCPCS Level II code S0189 Testosterone pellet, 75 mg or J3490 Unclassified drug, you may want to check with your payer to make sure your claims will be paid. TrailBlazer Health Enterprises, Medicare administrative contractor for jurisdiction 4 (J4-MAC), ...
In CMS
Oct 29th, 2010
Effective for service dates on or after Dec. 15, HCPCS Level II code J3490 Unclassified drugs will be non-covered as a self-administered drug when used to bill Medicare Part B for Hizentra™ (Immune Globulin Subcutaneous (Human) (IGSC)). This is in accordance with the recently updated Self-Administered Drug Exclusions List, TrailBlazer Health Enterprises announced Oct. 22 in a notice ...
In CMS
Feb 15th, 2010
The Centers for Medicare & Medicaid Services (CMS) has clarified the pricing for Ozurdex (dexamethasone, intravitreal) when billed using HCPCS Level II code J3490 Unclassified drugs with a description of “Ozurdex” in Item 19 of the CMS-1500 claim form or its electronic equivalent. Ozurdex Pricing Update was last modified: July 5th, 2011 by admin aapc...
In Coding
Oct 5th, 2009
Submitted by Marlene Doty, CPC, CUC, PCS A physician may offer a male patient diagnosed with low testosterone, or “Low T,” varying options of medical treatment to relieve symptoms. One of those options is testosterone replacement therapy, which consists of testosterone pellets inserted by subcutaneous implantation once every 3-6 months in the office. Before billing ...